Kailera Therapeutics is trading 4.7% down at $11.06; no clear company-specific announcement explaining the October 12 move surfaced. - The latest listed company release was October 1 and concerned EASD clinical data. - An October 14 lock-up expiration has been cited as a possible source of selling pressure, but reporting does not establish it as the cause of this decline. - Supplied broader market data do not show a significant same-direction move explaining the drop.